Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors

Parabilis Medicines announced updated Phase 1/2 data for zolucatetide, a first-in-class β-catenin:TCF inhibitor, showing a 72.2% objective response rate and 100% disease control rate in desmoid tumor patients at the 32-week landmark. The company has reached FDA alignment on the Phase 3 PEDESTAL trial design, dosing regimen, and primary endpoint, with trial initiation planned for H1 2027 and topline results expected in 2029.